Literature DB >> 1765865

Management of stage III pressure ulcers in moderately demented nursing home residents.

E L Siegler1, R Lavizzo-Mourey.   

Abstract

PURPOSE: To determine whether the myocutaneous flap procedure, the preferred treatment for young patients with stage III pressure ulcers, is appropriate for moderately demented nursing home residents. SUBJECTS AND METHODS: A model of the treatment decision was created using the decision-tree format. The probabilities of treatment outcomes in the decision tree were derived from the literature. Utilities for treatment outcomes were obtained from five internists, five geriatricians, six nurse practitioners, five plastic surgeons, and six lay people.
RESULTS: A majority in each group of respondents favored surgery, according to the decision analysis. Sensitivity analysis showed that surgery was preferred unless its success rate was less than 30%, or the rate of healing with conservative measures was at least 40%, which are unlikely values. Economic analysis demonstrated that surgery was $17,000 more expensive than conservative therapy.
CONCLUSION: The myocutaneous flap procedure is preferred by the majority of relevant decision makers when cost is not a consideration. The relative underutilization of surgery in practice has many possible explanations. The most likely are the failure of providers to appreciate the morbidity of pressure ulcers and the reluctance of practitioners to perform expensive procedures on demented patients.

Entities:  

Mesh:

Year:  1991        PMID: 1765865     DOI: 10.1007/bf02598218

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  23 in total

1.  The problem of pressure sores in a nursing home population: statistical data.

Authors:  R J Michocki; P P Lamy
Journal:  J Am Geriatr Soc       Date:  1976-07       Impact factor: 5.562

2.  Correlation of pressure sores and nutritional status.

Authors:  G D Pinchcofsky-Devin; M V Kaminski
Journal:  J Am Geriatr Soc       Date:  1986-06       Impact factor: 5.562

3.  Primary results following surgical treatment of pressure sores.

Authors:  M Pers; K Snorrason; I M Nielsen
Journal:  Scand J Plast Reconstr Surg       Date:  1986

4.  Sacral pressure sores: treatment with island gluteus maximus musculocutaneous flaps.

Authors:  R S Rees; A F Reilley; L B Nanney; J B Lynch
Journal:  South Med J       Date:  1985-10       Impact factor: 0.954

5.  The vastus lateralis myocutaneous flap.

Authors:  M A Drimmer; M J Krasna
Journal:  Plast Reconstr Surg       Date:  1987-04       Impact factor: 4.730

6.  Pressure ulcers in the elderly: prevention and treatment utilizing the team approach.

Authors:  J W Reed
Journal:  Md State Med J       Date:  1981-11

7.  The late results of surgical treatment of pressure sores in paraplegics.

Authors:  R B Berry
Journal:  Br J Surg       Date:  1980-07       Impact factor: 6.939

8.  Preventing pressure sores in hospital: controlled trial of a large-celled ripple mattress.

Authors:  M R Bliss; R McLaren; A N Exton-Smith
Journal:  Br Med J       Date:  1967-02-18

9.  Sepsis associated with decubitus ulcers.

Authors:  J E Galpin; A W Chow; A S Bayer; L B Guze
Journal:  Am J Med       Date:  1976-09       Impact factor: 4.965

10.  The need for skin and muscle saving techniques in the repair of decubitus ulcers. A consecutive series of 72 patients and 100 ulcers over 5 years (1979/1984). A case report.

Authors:  C Kauer; G Sonsino
Journal:  Scand J Plast Reconstr Surg       Date:  1986
View more
  3 in total

1.  Stage III pressure ulcers.

Authors:  D R Berlowitz; S V Wilking
Journal:  J Gen Intern Med       Date:  1992 Jul-Aug       Impact factor: 5.128

2.  Surgical treatment and strategy in patients with multiple pressure sores.

Authors:  I-Han Chiang; Chih-Hsin Wang; Yuan-Sheng Tzeng
Journal:  Int Wound J       Date:  2018-06-28       Impact factor: 3.315

Review 3.  [Reconstruction using the tensor fasciae latae muscle flap].

Authors:  R Ipaktchi; M K Boyce; T R Mett; P M Vogt
Journal:  Oper Orthop Traumatol       Date:  2018-06-27       Impact factor: 1.154

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.